Beijing Airdoc Technology Co. Ltd. Class H (HK:2251)
:2251
Want to see HK:2251 full AI Analyst Report?
2251 Stock Chart & Stats
HK$12.44
-HK$0.02(-0.17%)
At close: 4:00 PM EST
HK$12.44
-HK$0.02(-0.17%)
Day’s Range― - ―
52-Week RangeHK$10.02 - HK$16.00
Previous CloseN/A
Volume16.00K
Average Volume (3M)61.23K
Market Cap
HK$1.06B
Enterprise ValueHK$399.87M
Total Cash (Recent Filing)HK$650.73M
Total Debt (Recent Filing)HK$26.93M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding103,568,016
10 Day Avg. Volume99,440
30 Day Avg. Volume61,230
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)0.85
Price to Sales (P/S)6.06
P/FCF Ratio-49.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)HK$251.57M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Unit EconomicsRevenue rebound and a jump in gross margin to ~66% reflect improving unit economics and stronger product-market fit for its AI imaging software. Sustained top-line growth with high gross margins supports scalable software economics, enabling reinvestment into sales and R&D to pursue durable, profitable growth over the medium term.
Conservative Capital StructureVery low leverage provides meaningful financial flexibility and reduces near-term refinancing risk. With minimal debt service burden, management has capacity to fund commercialization and product development, absorb shocks, and extend runway while pursuing scale—important for durability over the next several quarters.
Recurring Software Model & Structural DemandA licensing/subscription/per-use model creates recurring revenue and scalable margins typical of software businesses. Focus on ophthalmology and chronic disease screening aligns with long-term healthcare digitization and screening trends, supporting durable demand and predictable revenue streams as adoption grows.
Bears Say
Persistent LossesA net margin near -14% means the company remains loss-making despite revenue and margin gains. Ongoing losses erode retained capital and limit the ability to self-fund expansion or cushion downturns. Over multiple quarters this raises the probability of external financing and potential dilution, constraining long-term sustainability.
Weak And Volatile Cash GenerationNegative operating and free cash flow in the latest year show the business is not consistently converting revenue into cash. This volatility increases dependence on external capital to fund operations and growth, reducing strategic flexibility and elevating execution and funding risk across the next 2-6 months.
Negative Return On EquityConsistently negative ROE indicates the company has not translated invested equity into profitable operations. Over time, persistent negative returns undermine investor confidence, make future equity raises harder or more dilutive, and signal that management must improve capital efficiency to create sustainable shareholder value.
Beijing Airdoc Technology Co. Ltd. Class H News
2251 FAQ
What was Beijing Airdoc Technology Co. Ltd. Class H’s price range in the past 12 months?
Beijing Airdoc Technology Co. Ltd. Class H lowest stock price was HK$10.02 and its highest was HK$16.00 in the past 12 months.
What is Beijing Airdoc Technology Co. Ltd. Class H’s market cap?
Beijing Airdoc Technology Co. Ltd. Class H’s market cap is HK$1.06B.
When is Beijing Airdoc Technology Co. Ltd. Class H’s upcoming earnings report date?
Beijing Airdoc Technology Co. Ltd. Class H’s upcoming earnings report date is Aug 21, 2026 which is in 92 days.
How were Beijing Airdoc Technology Co. Ltd. Class H’s earnings last quarter?
Beijing Airdoc Technology Co. Ltd. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.249 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.249.
Is Beijing Airdoc Technology Co. Ltd. Class H overvalued?
According to Wall Street analysts Beijing Airdoc Technology Co. Ltd. Class H’s price is currently Overvalued.
Does Beijing Airdoc Technology Co. Ltd. Class H pay dividends?
Beijing Airdoc Technology Co. Ltd. Class H does not currently pay dividends.
What is Beijing Airdoc Technology Co. Ltd. Class H’s EPS estimate?
Beijing Airdoc Technology Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Airdoc Technology Co. Ltd. Class H have?
Beijing Airdoc Technology Co. Ltd. Class H has 103,568,016 shares outstanding.
What happened to Beijing Airdoc Technology Co. Ltd. Class H’s price movement after its last earnings report?
Beijing Airdoc Technology Co. Ltd. Class H reported an EPS of -HK$0.249 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.051%.
Which hedge fund is a major shareholder of Beijing Airdoc Technology Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2251
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Airdoc Technology Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.07%
12-Months-Change
Fundamentals
Return on Equity
-1.97%
Trailing 12-Months
Asset Growth
-2.84%
Trailing 12-Months
Company Description
Beijing Airdoc Technology Co. Ltd. Class H
Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-based software as a medical device for auxiliary diagnosis of diabetic retinopathy; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; and Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia, retinal detachment, glaucoma detection, cataracts detection, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. The company also provides health risk assessment solutions to detect risk indicators, such as various lesions and diseases, hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation, and arteriosclerosis in a range of healthcare environments, including health checkup centers, community clinics, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices, including fundus cameras. The company was incorporated in 2015 and is headquartered in Beijing, China.
Technical Analysis
Yidu Tech, Inc.
―
Chaoju Eye Care Holdings Ltd.
―
Yunkang Group Limited
―
C-MER Eye Care Holdings Limited
―
SinoMab Bioscience Ltd.
―